Avastin (bevacizumab), significantly improves the time patients with advanced non-small cell lung cancer (NSCLC) live without their disease advancing (”progression free survival”) when added to cisplatin/gemcitabine chemotherapy, compared with chemotherapy alone. NSCLC is the most common form of the disease and accounts for more than 80 percent of all lung cancersii, with histology other than squamous cell as the most common subtype accounting for approximately 60 percent of NSCLC cases. [click link for full article]